Top ▲
This section gives an overview of the disease, and where available shows the following:
More information can be found in the help pages.
✖Disease ID: | 622 | |
Name: | Gastrointestinal neuroendocrine tumor | |
Associated with: | 1 target |
Database Links |
Disease Ontology:
DOID:4148 |
Click on the target name to link to its detailed view page
Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.
If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page
Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.
More information can be found in the help pages.
✖SST2 receptor | |
Role: | The randomized, placebo-controlled, prospective PROMID (placebo-controlled, double-blind, prospective randomized study) showed effect of octreotide LAR in the control of tumour growth in patients with metastatic midgut neuroendocrine tumors (NETs). |
References: | 1 |
Click ligand name to view ligand summary page
Click the arrow in the final column to expand comments
More information can be found in the help pages.
✖No ligand related data available for Gastrointestinal neuroendocrine tumor
1. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M et al.. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol, 27 (28): 4656-63. [PMID:19704057]